Influenza A Infections Global Clinical Trials Review, H1, 2016

Influenza A Infections Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Influenza A Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Influenza A Infections Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level



Companies Mentioned

GlaxoSmithKline Plc Novartis AG Sanofi Johnson & Johnson AstraZeneca Plc Microgen Scientific Industrial Company for Immunobiological Medicines F. Hoffmann-La Roche Ltd. Daiichi Sankyo Company, Limited Altimmune, Inc. CSL Limited


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Uremic (Renal) Pruritus Global Clinical Trials Review, H2, 2015

Uremic (Renal) Pruritus Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.Thisreport provides top line data relating to the clinical trials on Uremic (Renal) Pruritus. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Uremic (Renal) Pruritus Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Trevi Therapeutics, Inc. Cara Therapeutics, Inc. Toray Industries, Inc. PSI CRO AG Pfizer Inc. Almirall, S.A. Acologix, Inc. Maruishi Pharmaceutical Co., Ltd. DaVita HealthCare Partners Inc.


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Kenya Block 13T Complex Project Panorama - Oil and Gas Upstream Analysis Report

Kenya Block 13T Complex Project Panorama - Oil and Gas Upstream Analysis Report is a new market research publication announced by Reportstack.This upstream report includes detailed qualitative and quantitative information on the asset, provides a full economic assessment and reflects several parameters including (but not limited to) geological profile, asset development and specific challenges. Based on this analysis, future outlook for the asset is presented with possible trends and related scenarios identifying upside/downside potential.

Complete report available @ Kenya Block 13T Complex Project Panorama - Oil and Gas Upstream Analysis Report

Scope

- Overview of the asset based on an analysis of the economic indicators
- Key financial indicators including Net Present Value and Internal Rate of Return
- Review of factors affecting the economic outcome of the field including development overview, geology, challenges, reserves and production with qualitative perspective on of the overall assets life with analysis on the asset’s future outlook
- Detailed production profile for the asset, giving annual output rates for each commodity produced
- Cash flow statements from our economic analysis of the asset including capital expenditures, operating expenditures and tax liability
- Individual valuations for equity holders
- Sensitivity analysis for asset value considering a range of factors

Reasons to buy

- Understand the economic and non-economic factors that affect production of an asset
- Benefit from an asset valuation derived from detailed research and modeling by our analysts
- Basic view of various scenarios and its effect on the asset for risk or strategy planning
- Utilize the quantitative and qualitative evaluation to ascertain trends within the region to inform decision making
- Identify economic trends of an asset to determine investment requirements

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Influenza B Infections Global Clinical Trials Review, H1, 2016

Influenza B Infections Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This  report provides top line data relating to the clinical trials on Influenza B Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using  proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Influenza B Infections Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level



Companies Mentioned

GlaxoSmithKline Plc F. Hoffmann-La Roche Ltd. ID Biomedical Corporation Daiichi Sankyo Company, Limited MediVector, Inc. MDVIP, Inc. Biota Pharmaceuticals, Inc. Biological E. Limited Advanced Immunization Technologies ABX-CRO advanced pharmaceutical services Forschungsgesellschaft m.b.H


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Pandemic Influenza Global Clinical Trials Review, H1, 2016

Pandemic Influenza Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Pandemic Influenza. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Pandemic Influenza Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Novartis AG GlaxoSmithKline Plc AstraZeneca Plc Sanofi Novavax, Inc. CSL Limited Microgen Scientific Industrial Company for Immunobiological Medicines Johnson & Johnson Nanotherapeutics, Inc. Accelovance Inc.



 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Haemophilus influenzae Type B Infections Global Clinical Trials Review, H1, 2016

Haemophilus influenzae Type B Infections Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This  report provides top line data relating to the clinical trials on Haemophilus influenzae Type B Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Haemophilus influenzae Type B Infections Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

GlaxoSmithKline Plc Sanofi Novartis AG Merck & Co., Inc. LG Life Science LTD. PT Bio Farma Serum Institute of India Limited Novartis Vaccines and Diagnostics Srl Heber Biotec S. A National Dairy Development Board



 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Haemophilus influenzae Infections Global Clinical Trials Review, H1, 2016

Haemophilus influenzae Infections Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Haemophilus influenzae Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Haemophilus influenzae Infections Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

GlaxoSmithKline Plc Sanofi Novartis AG Panacea Biotec Limited Merck & Co., Inc. LG Life Science LTD. PT Bio Farma Serum Institute of India Limited Novartis Vaccines and Diagnostics Srl Heber Biotec S. A


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H1, 2016

H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This  report provides top line data relating to the clinical trials on H5N1 Infection (Avian Influenza). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H1, 2016


Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Companies Mentioned

GlaxoSmithKline Plc Novartis AG Microgen Scientific Industrial Company for Immunobiological Medicines Sanofi AstraZeneca Plc Nanotherapeutics, Inc. Mitsubishi Tanabe Pharma Corporation Johnson & Johnson Daiichi Sankyo Company, Limited Baxter International Inc.


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Peripheral Neuropathic Pain Global Clinical Trials Review, H1, 2016

Peripheral Neuropathic Pain Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Peripheral Neuropathic Pain. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Peripheral Neuropathic Pain Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Companies Mentioned

Eli Lilly and Company Pfizer Inc. Astellas Pharma Inc. GW Pharmaceuticals Plc C. H. Boehringer Sohn AG & Co. KG Quintiles Transnational Holdings Inc. Shionogi & Co., Ltd. ICON Plc Grunenthal GmbH AstraZeneca Plc


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Dengue Fever Global Clinical Trials Review, H1, 2016

Dengue Fever Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.
This report provides top line data relating to the clinical trials on Dengue Fever. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Dengue Fever Global Clinical Trials Review, H1, 2016


Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level



Companies Mentioned

Sanofi GlaxoSmithKline Plc Takeda Pharmaceutical Company Limited 60 Degrees Pharmaceuticals LLC Merck & Co., Inc. Quintiles Transnational Holdings Inc. Globavir Biosciences, Inc. Cerus Corporation Activistic Limited Abivax S.A.


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Filariasis Global Clinical Trials Review, H1, 2016

Filariasis Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Filariasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using  proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Filariasis Global Clinical Trials Review, H1, 2016


Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Companies Mentioned

Teva Pharmaceutical Industries Limited Johnson & Johnson International Trachoma Initiative GlaxoSmithKline Plc


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Low Cardiac Output Syndrome Global Clinical Trials Review, H1, 2016

Low Cardiac Output Syndrome Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Low Cardiac Output Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using  proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Low Cardiac Output Syndrome Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Tenax Therapeutics, Inc. PT Kalbe Farma Tbk Osypka Medical GmbH Ono Pharmaceutical Co., Ltd. Ludwig Boltzmann Gesellschaft Dalim BioTech Co., Ltd.



 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Bradycardia Global Clinical Trials Review, H1, 2016

Bradycardia Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Bradycardia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Bradycardia Global Clinical Trials Review, H1, 2016


Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

St. Vincent's Hospital Melbourne Pty Ltd Shijiazhuang Yiling Pharmaceutical Co., Ltd. Medtronic plc Les Laboratoires Servier SAS


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2016

Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Abdominal Aortic Aneurysms. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Companies Mentioned

AstraZeneca Plc Novartis AG Cardoz AB BUPA Meda AB Mater Health Services Ionis Pharmaceuticals, Inc. Fresenius SE & Co. KGaA Fonds NutsOhra Dr. Franz Kohler Chemie GmbH


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2016

Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2016 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Abdominal Aortic Aneurysms. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2016

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

AstraZeneca Plc Novartis AG Cardoz AB BUPA Meda AB Mater Health Services Ionis Pharmaceuticals, Inc. Fresenius SE & Co. KGaA Fonds NutsOhra Dr. Franz Kohler Chemie GmbH


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2015 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2015 in Pharmaceuticals is a new market research publication announced by Reportstack.This report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in December 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Complete report available @ Partnerships, Licensing, Investments and M&A Deals and Trends for December 2015 in Pharmaceuticals


Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Pelvic Inflammatory Disease (Pelvic Infections) Global Clinical Trials Review, H2, 2015

Pelvic Inflammatory Disease (Pelvic Infections) Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Pelvic Inflammatory Disease (Pelvic Infections). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Pelvic Inflammatory Disease (Pelvic Infections) Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Bayer AG Green Cross Holdings Corporation Pfizer Inc. Merck & Co., Inc. JLL Partners, Inc. Galenica Ltd. Cosmo Pharmaceuticals S.p.A Backahill AB Astellas Pharma Inc. Allergan Plc


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Pandemic Influenza Global Clinical Trials Review, H2, 2015

Pandemic Influenza Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Pandemic Influenza. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Pandemic Influenza Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Novartis AG GlaxoSmithKline Plc Sanofi Novavax, Inc. Nanotherapeutics, Inc. Microgen Scientific Industrial Company for Immunobiological Medicines Sinovac Biotech Ltd. Baxter International Inc. AstraZeneca Plc Johnson & Johnson


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Rotavirus Infections Global Clinical Trials Review, H2, 2015

Rotavirus Infections Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Rotavirus Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Rotavirus Infections Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

GlaxoSmithKline Plc Merck & Co., Inc. Serum Institute of India Limited Sanofi Bharat Biotech International Limited International Centre for Diarrhoeal Disease Research, Bangladesh Romark Laboratories, L.C. China National Pharmaceutical Group Corporation CD Pharma India Private Ltd. Biocon Limited

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Influenza B Infections Global Clinical Trials Review, H2, 2015

Influenza B Infections Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Influenza B Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Influenza B Infections Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

GlaxoSmithKline Plc ID Biomedical Corporation Daiichi Sankyo Company, Limited Sanofi MediVector, Inc. MDVIP, Inc. Biota Pharmaceuticals, Inc. Biological E. Limited Advanced Immunization Technologies ABX-CRO advanced pharmaceutical services Forschungsgesellschaft m.b.H


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Pseudomonas aeruginosa Infections Global Clinical Trials Review, H2, 2015

Pseudomonas aeruginosa Infections Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Pseudomonas aeruginosa Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Pseudomonas aeruginosa Infections Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Companies Mentioned

Gilead Sciences, Inc. Novartis AG Insmed Incorporated KaloBios Pharmaceuticals, Inc. PARI Medical Holding GmbH WhiteGlove Health, Inc. Polyphor Ltd. Pherecydes Pharma SA Bayer AG Achaogen Inc.


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Staphylococcus aureus Infections Global Clinical Trials Review, H2, 2015

Staphylococcus aureus Infections Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Staphylococcus aureus Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Staphylococcus aureus Infections Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level



Companies Mentioned

Merck & Co., Inc. AstraZeneca Plc Pfizer Inc. Khorakiwala Holdings and Investments Private Limited Allergan Plc GlaxoSmithKline Plc TaiGen Biopharmaceuticals Holdings Limited Theravance Biopharma, Inc. Quintiles Transnational Holdings Inc. Jaguar Holding Company II


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Chlamydia trachomatis Infections Global Clinical Trials Review, H2, 2015

Chlamydia trachomatis Infections Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Chlamydia trachomatis Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Chlamydia trachomatis Infections Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

International Trachoma Initiative Sandoz International GmbH Prokarium Limited ORBIS International Inmunotek S.L Grarbet Tehadiso Mahber Daiichi Sankyo Company, Limited Allergan Plc ActivBiotics Pharma, LLC


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Complicated Skin And Skin Structure Infections (cSSSI) Global Clinical Trials Review, H2, 2015

Complicated Skin And Skin Structure Infections (cSSSI) Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Complicated Skin And Skin Structure Infections (cSSSI). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Complicated Skin And Skin Structure Infections (cSSSI) Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level


Companies Mentioned

Evolva Holding SA Pfizer Inc. Merck & Co., Inc. Allergan Plc AstraZeneca Plc Cerexa, Inc. Cempra, Inc. Laboratory Corporation of America Holdings INC Research Holdings, Inc. Bayer AG


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Mycobacterium avium-Intracellulare Infections Global Clinical Trials Review, H2, 2015

Mycobacterium avium-Intracellulare Infections Global Clinical Trials Review, H2, 2015 is a new market research publication announced by Reportstack.This report provides top line data relating to the clinical trials on Mycobacterium avium-Intracellulare Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Clinical Trial Reports are generated using  proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Complete report available @ Mycobacterium avium-Intracellulare Infections Global Clinical Trials Review, H2, 2015

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months


Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Companies Mentioned

Pfizer Inc. Abbott Laboratories Insmed Incorporated Sanofi F. Hoffmann-La Roche Ltd. Amgen Inc.



 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from  proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015

Scope

- The report provides a snapshot of the global therapeutic landscape of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

A. Menarini Industrie Farmaceutiche Riunite Srl AB Science SA AbbVie Inc. Adamis Pharmaceuticals Corporation Advaxis, Inc. Aeterna Zentaris Inc. Alethia Biotherapeutics Inc. Ambrx, Inc. Amgen Inc. AnGes MG, Inc. Angion Biomedica Corp. Aphios Corporation Armour Therapeutics Inc. Arno Therapeutics, Inc. Arrowhead Research Corporation Astellas Pharma Inc. Astex Pharmaceuticals, Inc. AstraZeneca Plc ATLAB Pharma SAS Bavarian Nordic A/S Bayer AG Beta Pharma, Inc. BIND Therapeutics, Inc. Bio-Cancer Treatment International Limited Biscayne Pharmaceuticals, Inc. Boehringer Ingelheim GmbH Bristol-Myers Squibb Company CellCentric Ltd Celldex Therapeutics, Inc. Corcept Therapeutics Incorporated CureVac GmbH CytoVac A/S DexTech Medical AB Eisai Co., Ltd. Eli Lilly and Company Emergent BioSolutions Inc. Enceladus Pharmaceuticals BV Endo Pharmaceuticals Inc. EndoCeutics, Inc. Endocyte, Inc. Errant Gene Therapeutics, LLC ESSA Pharma Inc F. Hoffmann-La Roche Ltd. Fujifilm Corporation G1 Therapeutics, Inc. Genentech, Inc. GenSpera, Inc. Glactone Pharma AB GlaxoSmithKline Plc GTx, Inc. Hybrigenics S.A. Immunomedics, Inc. Incuron, LLC Io Therapeutics, Inc. Johnson & Johnson Jyant Technologies, Inc. Karyopharm Therapeutics, Inc. Kura Oncology, Inc. Mediolanum farmaceutici S.p.A. Medivation, Inc. Merck KGaA Millennium Pharmaceuticals, Inc. NewLink Genetics Corporation Novartis AG Oncogenex Pharmaceuticals, Inc. Oncolytics Biotech Inc. Onyx Pharmaceuticals, Inc. Orion Oyj Orphagen Pharmaceuticals, Inc. Panacela Labs, Inc. Pfizer Inc. Progenics Pharmaceuticals, Inc. Sanofi Sotio a.s. Sun Pharma Advanced Research Company Ltd. Supratek Pharma Inc. Synta Pharmaceuticals Corp. Taiho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Tesaro, Inc. Tokai Pharmaceuticals, Inc. TRACON Pharmaceuticals, Inc. Viralytics Ltd.



 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Dyslipidemia - Pipeline Review, H2 2015

Dyslipidemia - Pipeline Review, H2 2015 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Dyslipidemia - Pipeline Review, H2 2015

Scope

- The report provides a snapshot of the global therapeutic landscape of Dyslipidemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Dyslipidemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dyslipidemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dyslipidemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Acasti Pharma Inc. 43 Allergan Plc 44 Alnylam Pharmaceuticals, Inc. 45 Amgen Inc. 46 Arbutus Biopharma Corporation 47 Arisaph Pharmaceuticals, Inc. 48 Astellas Pharma Inc. 49 AstraZeneca Plc 50 AtheroNova Inc. 51 BASF SE 52 BCWorld Pharm Co. Ltd. 53 Cadila Pharmaceuticals Ltd. 54 Cardax Pharmaceuticals, Inc. 55 Catabasis Pharmaceuticals, Inc. 56 Cerenis Therapeutics Holding SA 57 Chong Kun Dang Pharmaceutical Corp. 58 CJ HealthCare Corp. 59 Connexios Life Sciences Pvt. Ltd. 60 CymaBay Therapeutics, Inc. 61 Daewoong Pharmaceutical Co., Ltd. 62 Daiichi Sankyo Company, Limited 63 Debiopharm International S.A. 64 Eli Lilly and Company 65 Gemphire Therapeutics Inc. 66 Genfit SA 67 GlaxoSmithKline Plc 68 HanAll Biopharma Co., Ltd. 69 Hanmi Pharmaceuticals, Co. Ltd. 70 Huons Co., Ltd. 71 Hyundai Pharmaceutical Co., Ltd. 72 Innovent Biologics, Inc. 73 IPCA Laboratories Limited 74 Isis Pharmaceuticals, Inc. 75 Jeil Pharmaceutical Co., Ltd. 76 Jenrin Discovery, Inc. 77 JW Pharmaceutical Corporation 78 Kissei Pharmaceutical Co., Ltd. 79 Kotobuki Pharmaceutical Co., Ltd. 80 Kowa Company, Ltd. 81 Kymab Limited 82 LG Life Science LTD. 83 Lipicard Technologies Limited 84 Lotus Pharmaceutical Co., Ltd. 85 Merck & Co., Inc. 86 Nimbus Therapeutics, LLC 87 Nippon Chemiphar Co., Ltd. 88 Pfizer Inc. 89 Pharmena SA 90 Prometheon Pharma, LLC 91 Protalix BioTherapeutics, Inc. 92 Sancilio & Company, Inc. 93 Takeda Pharmaceutical Company Limited 94 Thetis Pharmaceuticals LLC 95 Torrent Pharmaceuticals Limited 96 Viking Therapeutics, Inc. 97 Yuhan Corporation 98

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Metastatic Pancreatic Cancer - Pipeline Review, H2 2015

Metastatic Pancreatic Cancer - Pipeline Review, H2 2015 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Metastatic Pancreatic Cancer - Pipeline Review, H2 2015
Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

AbbVie Inc. Aduro BioTech, Inc. ArQule, Inc. Array BioPharma Inc. AstraZeneca Plc AVEO Pharmaceuticals, Inc. Axcentua Pharmaceuticals AB Biothera, Inc. Boehringer Ingelheim GmbH Boston Biomedical, Inc. Bristol-Myers Squibb Company Cantex Pharmaceuticals, Inc. Celgene Corporation Clovis Oncology, Inc. Cornerstone Pharmaceuticals, Inc. CTI BioPharma Corp. CytRx Corporation Eleison Pharmaceuticals, Inc. Eli Lilly and Company Ensol Biosciences Inc. Erytech Pharma SA F. Hoffmann-La Roche Ltd. Fountain Biopharma Inc. Gilead Sciences, Inc. GlaxoSmithKline Plc Halozyme Therapeutics, Inc. HanAll Biopharma Co., Ltd. Immodulon Therapeutics Ltd. Immunomedics, Inc. Incyte Corporation MabVax Therapeutics Holdings, Inc. MedImmune, LLC Merck & Co., Inc. Merrimack Pharmaceuticals, Inc. NanoCarrier Co., Ltd. Nanotherapeutics, Inc. NantKwest, Inc. Natco Pharma Limited NewLink Genetics Corporation Novartis AG Oncolytics Biotech Inc. Oncovir, Inc. Oryx GmbH & Co. KG Pfizer Inc. Pharma Mar, S.A. Pharmacyclics, Inc. Phoenix Biotechnology, Inc. Precision Biologics, Inc. Redx Pharma Plc Rexahn Pharmaceuticals, Inc. Sanofi Silence Therapeutics Plc Targovax AS Teva Pharmaceutical Industries Limited Verlyx Pharma Inc. Zeria Pharmaceutical Co., Ltd.

 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015

Scope

- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Wet (Neovascular / Exudative) Macular Degeneration and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Wet (Neovascular / Exudative) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Wet (Neovascular / Exudative) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Aciont Inc. Allergan Plc Amakem NV Apellis Pharmaceuticals, Inc. Apexigen, Inc. Applied Genetic Technologies Corporatio Avalanche Biotechnologies, Inc. Benitec Biopharma Limited BIOCAD Boehringer Ingelheim GmbH Charlesson LLC. Chong Kun Dang Pharmaceutical Corp. Circadian Technologies Limited Clanotech AB Clearside BioMedical, Inc. Daiichi Sankyo Company, Limited Eleven Biotherapeutics Inc. Exonate Limited F. Hoffmann-La Roche Ltd. Formycon AG GTx, Inc. iCo Therapeutics Inc. Icon Bioscience, Inc. Kala Pharmaceuticals, Inc. Mabion SA Mitotech S.A. Neurotech Pharmaceuticals, Inc. Novartis AG Ocular Therapeutix, Inc. Ohr Pharmaceutical Inc. Ophthotech Corp. Oxford BioMedica Plc PanOptica, Inc. Pfenex Inc. Pfizer Inc. Quark Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. RegenxBio Inc. RXi Pharmaceuticals Corporation Santen Pharmaceutical Co., Ltd. Sanwa Kagaku Kenkyusho Co., Ltd. TRACON Pharmaceuticals, Inc. TWi Pharmaceuticals, Inc. Tyrogenex, Inc. Xbrane Bioscience AB


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###